The AACE Algorithm on obesity/ABCD care provides detailed guidance on various aspects of management such as screening, diagnosis, tailored plans, therapy response, medication hierarchies, individualized pharmacotherapy, & FDA-approved treatments.

Blood glucose–lowering therapy begins with lifestyle modification and metformin, with SGLT2 inhibitors or GLP-1 receptor agonists added based on cardio-renal risk and obesity status. Insulin is initiated when glycaemic targets are not achieved with optimized non-insulin therapy, with ongoing monitoring and adjustment through intensification or deintensification to maintain safety and control.